Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the trans-atlantic prostate group study Journal Article

   

Authors:	Berney, D. M.; Gopalan, A.; Kudahetti, S.; Fisher, G.; Ambroisine, L.; Foster, C. S.; Reuter, V.; Eastham, J.; Møller, H.; Kattan, M. W.; Gerald, W.; Cooper, C.; Scardino, P.; Cuzick, J.
Article Title:	Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the trans-atlantic prostate group study
Abstract:	Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Δχ<sup>2</sup> (1 d.f.)=24.6 (P=0.0001), overall survival χ<sup>2</sup>=20.5 (P=0.0001), and for the quantitative method, Δχ<sup>2</sup> (1 d.f.)=15.1 (P=0.0001), overall survival χ<sup>2</sup>=10.85 (P=0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the most promising biomarker to be applied into routine practice. © 2009 Cancer Research.
Keywords:	immunohistochemistry; cancer survival; major clinical study; overall survival; cancer localization; cancer patient; outcome assessment; cancer diagnosis; diagnostic accuracy; ki 67 antigen; ki-67 antigen; prostate specific antigen; biological markers; cohort analysis; tumor marker; prostate cancer; gleason score; prostatic neoplasms; conservative treatment; quantitative analysis; active surveillance; biomarker; ki-67; watchful waiting; cancer specific survival; laboratory test
Journal Title:	British Journal of Cancer
Volume:	100
Issue:	6
ISSN:	0007-0920
Publisher:	Nature Publishing Group
Date Published:	2009-03-24
Start Page:	888
End Page:	893
Language:	English
DOI:	10.1038/sj.bjc.6604951
PUBMED:	19293807
PROVIDER:	scopus
PMCID:	PMC2661778
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-62549130773&partnerID=40&md5=53b0ad01af74ceb28c112d056e59ffee
Notes:	--- - "Cited By (since 1996): 6" - "Export Date: 30 November 2010" - "CODEN: BJCAA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/122